Inhalation Sciences Q2’22: Our comments - Redeye

Redeye comments on Inhalation Sciences Q2’22 report. We are positive about the order backlog decrease but hope to see an increased order intake going forward. Overall, we are excited about ISAB’s second half of the year as we hope to see activity with current and new customers. We make slight adjustments in our FY’22 forecast and reiterate our Base Case to SEK 23.

Länk till analysen i sin helhet: https://www.redeye.se/research/854008/inhalation-sciences-q222-our-comments?utm_source=finwire&utm_medium=RSS